Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. - Wikidata - wikimedia - TriplyDB

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q34036872

about

Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives Novel bile acid therapeutics for the treatment of chronic liver diseases Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD Nonalcoholic fatty liver disease: new treatments Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices The impact of PPARα activation on whole genome gene expression in human precision cut liver slices Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPARα and L-FABP Expressions in High-Fat-Fed Rats Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Promising therapies for treatment of nonalcoholic steatohepatitis.miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.Pathobiology of liver fibrosis: a translational success story Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Transcriptomic signatures of peroxisome proliferator-activated receptor α (PPARα) in different mouse liver models identify novel aspects of its biology.Cyclosporin A induced toxicity in mouse liver slices is only slightly aggravated by Fxr-deficiency and co-occurs with upregulation of pro-inflammatory genes and downregulation of genes involved in mitochondrial functions.Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy.S-Propargyl-cysteine Exerts a Novel Protective Effect on Methionine and Choline Deficient Diet-Induced Fatty Liver via Akt/Nrf2/HO-1 Pathway.Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression.Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.PPARs and Mitochondrial Metabolism: From NAFLD to HCC.Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice Evolving therapies for non-alcoholic steatohepatitis.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.PPARα-dependent Insig2a overexpression inhibits SREBP-1c processing during fasting Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Pharmacotherapy for Nonalcoholic Fatty Liver Disease.Review article: new treatments in non-alcoholic fatty liver disease.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.

P2860

Q24563381-33C9AB52-55DD-46C5-82C4-26BB5825EAE7 Q26747009-AFB6C843-EE1F-42A7-BD37-7691F9222960 Q26748613-B64C1309-C383-4EF2-BED5-C926856767E2 Q26751258-B59854FE-6884-4DFF-B885-9BFB54C9B6D3 Q26752487-D4FEEE5E-CEF8-415D-AADC-8D29D7CDFF73 Q27021161-1040108B-3219-4005-902C-1E92882A3009 Q27021577-A4674A10-A090-4727-AE2B-D97D18AA12CB Q27336127-88F1513A-B922-408D-8869-C0747A965071 Q28539289-296657D3-1B2F-41C9-A4FA-7516A4428858 Q28606579-36822058-733F-4402-BDCD-D89B75FF66C2 Q28817618-2A3D2CC4-73A8-4440-8803-2C9771791041 Q30234444-B6066F4F-0EC1-4C2F-9281-F064D1A0BFC0 Q30241952-AD8BE501-1BEE-4E25-A0C2-056DDD73EE4F Q30248578-981854EA-D132-4A20-A5C5-98257A3EBA9F Q33815927-4D9AC275-C391-47DC-B90B-82B4A21CDA83 Q33877800-DDEB14B5-15BF-4FD5-B17D-802E0A572844 Q34041838-549FF376-6168-43C7-AA6C-72A6864F24D5 Q34041987-CCE52596-495D-445F-BF42-AA9A017AD71B Q34398065-E141A286-9535-421A-94A3-74DEB7CC16F3 Q34412650-8067C866-8528-4270-9AB1-3EB3B980BA37 Q34462733-829D3AA2-C951-4816-9F4A-F515538488D9 Q34540703-8BCE4EF3-19B6-40D9-9BE6-A3501880889B Q35228774-198F74A1-1190-465B-980E-85E5D62EA7A2 Q35813594-6CD2132D-7890-4E45-9C69-D2848B0F5DE3 Q36159376-D6EA8A6C-9FDD-4304-8383-2B077A50D5AB Q36203522-07352CDC-83CE-4263-8934-0D09D55FEB67 Q36969802-3C989FE1-8141-43D1-95CE-1B118DFE32CC Q37398932-647ADB05-8E73-4C23-9EA6-0D7824ABC4A1 Q37563673-31C785AF-B864-433D-8122-6FA126FAF421 Q37575571-55805D79-083C-41A3-8E70-82567B0F71E7 Q37578702-BCF8C18E-A7FD-4EC3-94BD-E364C0CEDC36 Q37613094-D7EC1D4C-F714-400F-86D1-6186AF472C73 Q38207111-01BADE44-F459-4CA7-B3B6-70B3ED4727EE Q38325814-012186F1-5104-4E86-BDDA-DF888CE29081 Q38399125-4B9EAE72-79CA-40E5-933C-F12EB4E653D6 Q38580461-DB2BC868-DF29-4756-9AA3-687E571B69BB Q38588344-8286CED9-52B9-4C74-A41D-F11A2B5932FB Q38662765-6E0FE572-0142-494A-A44B-A8EEF4B524B6 Q38674739-D341E787-304F-402E-B9A6-DE90648EE68C Q38674742-3471E04B-7BAE-43F3-96E2-2B5C03B4059E

P2860

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q34036872

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@ast

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@en

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@nl

type

label

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@ast

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@en

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@nl

prefLabel

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@ast

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@en

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@nl

P1433

Q34036872-00439A49-74A5-4DCB-B264-D6D37405415C

P1476

Q34036872-45ACCC75-AEF1-4662-A05C-A4ECC792491D

P2093

Q34036872-12FFB0D5-9710-4760-AEC4-130ECBF2B666

Q34036872-18FA5064-96D0-4105-86E7-52F40A3BE176

Q34036872-1B86FFC0-8984-4208-957A-0A6643CA871E

Q34036872-38270A70-76B2-4776-BD08-32B46873E60D

Q34036872-88DA58E6-190C-4F20-A5D1-646578193401

Q34036872-AF9499EE-DE4C-43C0-BE13-C0FE3EEAEC01

Q34036872-B17A18B3-1EEF-42F7-A01C-F84BBF398921

Q34036872-B817B16C-F428-42D5-B5AC-05CD563F9D5F

Q34036872-E654D3B1-DE25-44F7-8135-225FA13DC688

Q34036872-EC9BABF9-D801-4886-811A-7359DDE1D875

P304

Q34036872-ADE40FA5-2FE8-422A-97CE-C4933F200AF8

P31

Q34036872-80ABBAAD-2BE7-4C6A-B7C8-506A429454E7

P356

Q34036872-EE6B27C3-54C5-4E82-9737-1C6C0CEE5D01

P407

Q34036872-DA3CA418-D54D-4E26-AB6D-B3BF23BDFD58

P433

Q34036872-9DCD8614-C5AE-4125-84F3-C93CAE4F8FFB

P478

Q34036872-0DB8CD29-20E7-40AE-830F-242F0469148C

P50

Q34036872-0A8499B0-0ECF-4812-B3C0-A76509FBFCF9

Q34036872-E84218FB-521A-4334-B7D3-A40B0AB2E522

P577

Q34036872-62148704-7754-43CA-97EE-E677E6019369

P5875

Q34036872-113E19B9-B714-4BB7-B7C1-6F2429D94E58

P698

Q34036872-8CD3A475-6AB4-41AD-AFE0-ABD64D1353AD

P921

Q34036872-BDD30527-9AFB-4115-81CA-45A20320D51B

P356

P1433

P1476

Hepatoprotective effects of th ...... /nonalcoholic steatohepatitis.

@en

P2093

Anne Rubenstrunk

http://www.w3.org/2001/XMLSchema#string

Anthony Lucas

http://www.w3.org/2001/XMLSchema#string

Benoit Noel

http://www.w3.org/2001/XMLSchema#string

Bertrand Cariou

http://www.w3.org/2001/XMLSchema#string

Dean W Hum

http://www.w3.org/2001/XMLSchema#string

Géraldine Rigou

http://www.w3.org/2001/XMLSchema#string

Lesley J Millatt

http://www.w3.org/2001/XMLSchema#string

Morgane Baron

http://www.w3.org/2001/XMLSchema#string

Philippe Delataille

http://www.w3.org/2001/XMLSchema#string

Rémy Hanf

http://www.w3.org/2001/XMLSchema#string

P304

1941-1952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26461

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259538185

http://www.w3.org/2001/XMLSchema#string

P698

23703580

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis